Paul H. Flowers Jr.Senior Business Consultant, Superior Insurance Advisors, LLC · 2024 Hot 100 honoree. 2026 Health Value Award. Fiduciary process documented. 30 to 40 percent health-plan savings for 100 to 2,000 employee CFOs. 3x number one bestseller.

Who Really Writes Your Company's Drug List?

7 Aug 2026 · 1 min

Watch on YouTube

0:48

In this brief monologue, Paul H. Flowers Jr. explains how pharmacy benefit managers and other intermediaries determine a company's drug formulary not based on clinical effectiveness but on the size of rebates tied to a drug's list price. He describes the incentive structure: higher list prices generate larger rebates for the middlemen, leading to expensive brand‑name drugs being favored while cheaper generics disappear. This results in patients paying higher coinsurance on inflated prices, even though the invoice may label the rebate as a "discount." Flowers urges viewers to read their formulary, investigate who constructed it, and understand the financial motivations behind drug selection, emphasizing that the list price is driven by profit margins rather than patient health.

Chapters

Somewhere between your doctor's pen and the pharmacy counter, a stranger decided which drugs your plan prefers. Not because they work better, because they pay better. The middleman's rebate is a percentage of the list price. Higher sticker, bigger cut. So the $1,000 brand makes the list, and the $40 generic quietly disappears. Your people pay coinsurance on the inflated number. The invoice calls it a discount. Every incentive in that chain points up. I'm done pretending that's a benefit. Read your formulary. Ask who built it. Ask what they were paid to prefer. The list was never about your health, it was about their margin. I'm Paul H. Flowers Jr. and I stopped taking the list at face value.